International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown, P. 125747 - 125747
Published: May 1, 2025
Language: Английский
International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown, P. 125747 - 125747
Published: May 1, 2025
Language: Английский
Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(3), P. 290 - 290
Published: Feb. 20, 2025
Objectives: This study aimed to develop hesperidin solid lipid nanoparticles (HESP-SLNs) enhance their stability, solubility, and sustained release for wound healing; further enhancement was achieved through prepared nanostructured carriers (HESP-NLCs) using Tea Tree Oil (TTO) explore synergistic efficacy. Methods: A factorial design of 24 trials established evaluate the influence type (X1), conc (%) (X2), surfactant (X3), sonication amplitude (X4) HESP-SLNs on particle size (nm) (Y1), polydispersibility index (Y2), zeta potential (Y3), encapsulation efficiency (Y4). The optimized formula selected utilizing Design Expert® software version 13, which additionally enhanced by preparing TTO-loaded HESP-NLCs. In vitro release, Raman spectroscopy, transmission electron microscopy were carried out both nanoparticles. Cytotoxicity, in vivo wound-healing assessments, skin irritancy tests performed performance TTO-incorporated HESP-NLCs compared HESP-SLNs. Results: demonstrated PS (280 ± 1.35 nm), ZP (−39.4 0.92 mV), PDI (0.239 0.012), EE% (88.2 2.09%). NLCs Q6% (95.14%) vs. (79.69%), SLNs showed superior antimicrobial Both exhibited spherical morphology compatibility between HESP excipients. highest closure percentage, supported histological analysis inflammatory biomarker outcomes. Cytotoxicity evaluation 87% cell viability untreated HSF cells, test confirmed safety NLCs. Conclusions: are promising candidates exhibiting capabilities, making them a therapeutic option cutaneous management.
Language: Английский
Citations
2Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(4), P. 463 - 463
Published: April 2, 2025
Background: Cannabidiol (CBD) is a natural compound from the Cannabis sativa L. plant, which has anti-inflammatory, anti-nociceptive, neuroprotective, and antibacterial activities. Objective: The aim of this study was to develop sustained-release device CBD that can provide an effect against Gram-positive bacteria Streptococcus mutans Staphylococcus aureus for extended periods time. Methods: incorporated into biodegradable PURASORB 5010 or 7510 DL-lactide/glycolide polymers using either dimethylsulfoxide (DMSO) acetone as solvent, dried polymer scaffolds were exposed daily fresh culture bacteria. bacterial growth determined by optical density, metabolic activity biofilms MTT assay. Biofilm formation on visualized HR-SEM. Its anti-inflammatory measuring IL-6 release LPS-stimulated RAW 264.7 macrophages ELISA. Cell cytotoxicity normal Vero epithelial cells gas chromatography–mass spectrometry (GC-MS). Results: 5010/CBD had S. UA159, ATCC25923, clinical isolate multidrug-resistant (MDRSA CI-M) strain tested period up 17 days. 7510/CBD also activity, but overall, it less effective than over addition PEG400 copolymers significantly increased not 5010/CBD. sufficient reduce LPS-induced secretion macrophages, importantly, cytotoxic cells. found be between 1.12 9.43 µg/mL, far below dose 25 µg/mL. Conclusions: incorporation used prepare devices medical purposes where combined activities are desirable.
Language: Английский
Citations
0Journal of Cluster Science, Journal Year: 2025, Volume and Issue: 36(3)
Published: April 4, 2025
Language: Английский
Citations
0ACS Omega, Journal Year: 2025, Volume and Issue: unknown
Published: May 22, 2025
Language: Английский
Citations
0International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown, P. 125747 - 125747
Published: May 1, 2025
Language: Английский
Citations
0